Smart Precision Medicine Software Market Report 2026

The smart precision medicine software market size has grown rapidly in recent years. It will grow from $3.42 billion in 2025 to $4.03 billion in 2026 at a compound annual growth rate (CAGR) of 17.9%. The growth in the historic period can be attributed to advances in clinical data digitization, expansion of genomic research databases, increasing adoption of electronic health records, growth of personalized medicine programs, availability of high-performance computing infrastructure.

The smart precision medicine software market size is expected to see rapid growth in the next few years. It will grow to $7.69 billion in 2030 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to growing demand for real-time personalized treatment insights, rising investments in ai-powered healthcare software, expansion of precision oncology and rare disease programs, increasing regulatory support for digital health, advancements in secure health data sharing. Major trends in the forecast period include increasing deployment of AI-driven clinical decision support, growing integration of genomic and clinical data platforms, rising adoption of cloud-based precision medicine solutions, expansion of predictive analytics in treatment planning, enhanced focus on interoperability and data security.

The growing demand for personalized healthcare is expected to drive growth in the smart precision medicine software market in the coming years. Personalized healthcare involves customizing medical treatments based on an individual’s unique genetic, environmental, and lifestyle profile. The rise in personalized healthcare is fueled by advances in genomic and molecular profiling, which enable therapies tailored to a patient’s genetics, improving effectiveness and minimizing side effects. Smart precision medicine software supports personalized healthcare by analyzing a patient’s genetic, clinical, and lifestyle information to recommend customized treatment plans, improve decision-making, forecast therapy responses, and optimize outcomes while reducing side effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing demand for personalized healthcare is propelling the growth of the smart precision medicine software market.

Leading companies in the smart precision medicine software market are focusing on innovations such as AI-enabled care pathway platforms to streamline clinical decision-making and improve patient outcomes. A care pathway intelligence platform evaluates patient data to create optimized, personalized treatment pathways, enhancing care efficiency and outcomes. For instance, in April 2024, Tempus, a U.S.-based provider of AI and precision medicine, launched Tempus Next, an AI-enabled care pathway intelligence platform. The platform uses AI to identify care gaps and provides clinicians with actionable, guideline-based insights at the point of care, integrating multimodal data from electronic medical records. It aims to accelerate precision medicine adoption and improve patient outcomes, initially focusing on oncology, including lung and breast cancer. The platform has screened thousands of patients across provider networks to help close critical care gaps and support real-time, personalized treatment decisions.

In May 2025, GeneDx, a U.S.-based provider of improved health outcomes through genomic insights, acquired Fabric Genomics for an undisclosed amount. This acquisition aims to enhance GeneDx’s capabilities in decentralized, AI-powered genomic testing, expanding its reach in neonatal and pediatric care. Fabric Genomics is a U.S.-based provider of AI-driven genomic interpretation software solutions.

Major companies operating in the smart precision medicine software market are Oracle Corporation, Siemens Healthineers AG, IQVIA Holdings Inc., Agilent Technologies Inc., Illumina Inc., Epic Systems Corporation, Athenahealth, Tempus AI Inc., Flatiron Health Inc., Human Longevity Inc., SOPHiA GENETICS SA, Velsera Inc., PierianDx Inc., 2bPrecise Inc., Translational Software Inc., Golden Helix Inc., PhenoTips Inc., bio.logis digital health GmbH, Geneyx Genomex Ltd., Fabric Genomics Inc.

North America was the largest region in the smart precision medicine software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the smart precision medicine software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart precision medicine software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the smart precision medicine software market by increasing costs of imported cloud infrastructure hardware, advanced computing components, data security solutions, and specialized software development tools. Healthcare providers and research organizations in North America and Europe are most affected due to reliance on global technology supply chains, while Asia-Pacific faces higher costs for software deployment and scaling. These tariffs are raising implementation costs and slowing digital transformation projects. However, they are also encouraging local software development, regional cloud partnerships, and innovation in cost-efficient precision medicine platforms.

The smart precision medicine software market research report is one of a series of new reports that provides smart precision medicine software market statistics, including smart precision medicine software industry global market size, regional shares, competitors with a smart precision medicine software market share, detailed smart precision medicine software market segments, market trends and opportunities, and any further data you may need to thrive in the smart precision medicine software industry. This smart precision medicine software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Smart precision medicine software refers to advanced digital platforms that process complex patient data to support personalized medical decisions. It combines clinical, genomic, and health information to generate actionable insights for optimized treatment strategies. This software enhances decision-making accuracy and improves patient outcomes through data-driven intelligence, with its main advantage being the efficient and consistent delivery of tailored healthcare recommendations.

The main types of smart precision medicine software include data analysis, data management, and others. Data analysis involves examining complex biological and clinical datasets to derive actionable insights for personalized patient care. Technologies used include artificial intelligence and machine learning (AI/ML), bioinformatics tools, cloud computing, blockchain, and wearable technology integration. These solutions are delivered through on-premise, cloud-based, hybrid platforms, mobile applications, and software-as-a-service (SaaS). Applications cover clinical decision support systems (CDSS), genetic disease management, personalized drug discovery, therapeutic monitoring, and patient management, serving end-users such as healthcare providers, pharmaceutical companies, research organizations, diagnostic laboratories, and healthcare IT vendors.

The smart precision medicine software market consists of revenues earned by entities by providing services such as patient data analytics, AI-driven treatment recommendations, clinical decision support solution, personalized therapy planning, and integration with healthcare systems for optimized patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The smart precision medicine software market also includes sales of genomic analysis platforms, AI-based diagnostic software, treatment optimization applications, and patient management systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.